Impact of Herpes Zoster Vaccine on Postherpetic Neuralgia: A Comprehensive Review

REVIEW
Ramadan S. Hussein, Salman Bin Dayel, Othman Abahussein, Waled Kamal Abdelbasset, Osama Mahfouz

 
For citation: Hussein RS, Dayel SB, Abahussein O, Abdelbasset WK, Mahfouz O. Impact of Herpes Zoster Vaccine on Postherpetic Neuralgia: A Comprehensive Review. International Journal of Biomedicine. 2025;15(4):649-652. doi:10.21103/Article15(4)_RA5
 
Originally published December 5, 2025

Abstract: 

Background: Herpes zoster (HZ), also known as shingles, is often complicated by postherpetic neuralgia (PHN), a chronic pain condition that significantly impairs quality of life. Vaccination against HZ has become a key preventive strategy to lower the risk of PHN. This review evaluates the effectiveness of HZ vaccines in reducing the incidence of PHN.
Methods and Results: In accordance with PRISMA guidelines, a systematic search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library up to May 2024. Eligible studies included randomized controlled trials (RCTs), cohort studies, and observational studies that reported quantitative outcomes on the occurrence of PHN after vaccination.
The included studies encompassed diverse populations, primarily older adults. The recombinant zoster vaccine (RZV) demonstrated a substantial reduction in PHN incidence, with effectiveness approaching 60%. In contrast, the live zoster vaccine (ZVL) showed notable early protection, though its efficacy declined over time. RZV was associated with higher rates of mild, self-limiting adverse reactions compared with ZVL.
Conclusions: Both HZ vaccines, particularly RZV, are effective in preventing PHN and exhibit acceptable safety profiles. Broader vaccine uptake could decrease the public health burden of PHN. Long-term data on the duration of immunity and the potential role of booster doses remain areas for future investigation.

Keywords: 
herpes zoster • neuralgia • vaccine
References: 
  1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun 10;4(6):e004833. doi: 10.1136/bmjopen-2014-004833. PMID: 24916088; PMCID: PMC4067812.
  2. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med. 2014 Oct 16;371(16):1526-33. doi: 10.1056/NEJMcp1403062. PMID: 25317872.
  3. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4. PMID: 18528318.
  4. Schmader KE, Oxman MN. Varicella and herpes zoster. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020. p. 1665-77.
  5. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. PMID: 27626517.
  6. Curran D, Bitetti J, Catterall I, Wincott S. Herpes zoster in older adults: Impact on carbon footprint in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2335722. doi: 10.1080/21645515.2024.2335722. Epub 2024 May 3. PMID: 38698759; PMCID: PMC11073404.
  7. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. J Infect Dis. 2016 Jun 15;213(12):1872-5. doi: 10.1093/infdis/jiw047. Epub 2016 Feb 9. PMID: 26908728.
  8. Gagliardi AM, Andriolo BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2016 Mar 3;3(3):CD008858. doi: 10.1002/14651858.CD008858.pub3. Update in: Cochrane Database Syst Rev. 2019 Nov 7;2019(11). doi: 10.1002/14651858.CD008858.pub4. PMID: 26937872; PMCID: PMC6516976.
  9. Drolet M, Levin MJ, Schmader KE, et al. A National Study of the Impact of Herpes Zoster Vaccine on the Burden of Disease. J Infect Dis. 2016;213(12):1876-1882. doi:10.1093/infdis/jiv641.
  10. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5. PMID: 29370152; PMCID: PMC5812314.
  11. Li Y, Fang L, Zhang Q, Zhang J, Xia N, Wang Q. Effectiveness of Herpes Zoster Vaccine in Reducing the Incidence of Postherpetic Neuralgia: A Meta-Analysis. BMC Geriatr. 2020;20(1):310. doi:10.1186/s12877-020-01675-1.
  12. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012 Apr;54(7):922-8. doi: 10.1093/cid/cir970. Epub 2012 Jan 30. PMID: 22291101; PMCID: PMC4542655.
  13. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28. PMID: 25916341.
  14. Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095. PMID: 29529222; PMCID: PMC5946839.
  15. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000 Mar 2;342(9):635-45. doi: 10.1056/NEJM200003023420906. Erratum in: N Engl J Med 2000 Apr 6;342(14):1063. PMID: 10699164.
  16. Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain. 2002 Mar;96(1-2):9-12. doi: 10.1016/s0304-3959(01)00400-6. PMID: 11932056.
  17. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun 10;4(6):e004833. doi: 10.1136/bmjopen-2014-004833. PMID: 24916088; PMCID: PMC4067812.
  18. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007 Nov;7(11):1581-95. doi: 10.1586/14737175.7.11.1581. PMID: 17997705.
  19. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013 Jul 18;369(3):255-63. doi: 10.1056/NEJMcp1302674. PMID: 23863052; PMCID: PMC4789101.
  20. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007 Nov;82(11):1341-9. doi: 10.4065/82.11.1341. Erratum in: Mayo Clin Proc. 2008 Feb;83(2):255. PMID: 17976353.
  21. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, van Wijck AJ, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26. doi: 10.1086/510206. PMID: 17143845.
  22. Lapolla W, Digiorgio C, Haitz K, Magel G, Mendoza N, Grady J, Lu W, Tyring S. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol. 2011 Aug;147(8):901-7. doi: 10.1001/archdermatol.2011.81. Epub 2011 Apr 11. PMID: 21482862.
  23. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x. Epub 2010 Apr 9. PMID: 20402746.
  24. GlaxoSmithKline. Shingrix (Zoster Vaccine Recombinant, Adjuvanted) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2019.
  25. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271-84. doi: 10.1056/NEJMoa051016. PMID: 15930418.
  26. Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of herpes zoster in patients with altered immune function. Epidemiol Infect. 2018;146(4):419-429.
  27. Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, Levin MJ. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. J Infect Dis. 2019 Jan 7;219(2):335-338. doi: 10.1093/infdis/jiy514. PMID: 30165651.
  28. Giannelos N, Ng C, Curran D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. Hum Vaccin Immunother. 2023 Dec 31;19(1):2168952. doi: 10.1080/21645515.2023.2168952. Epub 2023 Mar 14. PMID: 36916240; PMCID: PMC10054181.
  29. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Kim DK, Pilishvili T, Hales CM, Markowitz LE; Centers for Disease Control and Prevention (CDC). Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. MMWR Morb Mortal Wkly Rep. 2015 Feb 6;64(4):95-102. PMID: 25654611; PMCID: PMC4584858.
  30. Hechter RC, Tartof SY, Jacobsen SJ, Smith N, Tseng HF. Trends and disparity in zoster vaccine uptake in a managed care population. Vaccine. 2013 Sep 23;31(41):4564-8. doi: 10.1016/j.vaccine.2013.07.053. Epub 2013 Aug 5. PMID: 23928461.

Download Article
Received July 17, 2025.
Accepted September 22, 2025.
©2025 International Medical Research and Development Corporation.